miR-486、miR-499在肺癌患者血浆中的表达及临床价值  

The expression and clinical significance of plasma miR-486 and miR-499 in patients with lung cancer

作　　者：杨阳[1,2] 杨晴 贾友超[2] 李小芳[2] 杨华[2] 张倩[2] 彭鑫宇[4] 臧爱民[2] 

机构地区：[1]河北大学,071002 [2]河北省放化疗机制与规程重点实验室,河北大学附属医院肿瘤内科 [3]河北大学附属医院输血科 [4]河北大学附属医院肝胆外科

出　　处：《天津医药》2016年第11期1367-1370,共4页Tianjin Medical Journal

基　　金：2015年河北省政府资助临床医学优秀人才项目(361007)

摘　　要：目的：探讨miR-486和miR-499在肺癌患者血浆中的表达及临床意义，分析其在非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）中表达的差异。方法收集35例肺癌患者（其中NSCLC组21例，SCLC组14例）及30例健康者（对照组）血样标本，运用qPCR的方法测定各组血浆miR-486、miR-499的表达量，分析NSCLC和SCLC患者血浆中miR-486和miR-499的表达量与各临床特征的关系。对所有入组者血浆miRNA的相对表达量进行ROC曲线分析，计算曲线下面积（AUC）、最佳临界值及其敏感度和特异度。结果 NSCLC和SCLC组中血浆miR-486、miR-499的相对表达量均低于对照组（P＜0.05）。NSCLC组血浆miR-486在不同临床特征患者间表达差异均无统计学意义；而TNM分期越晚、分化程度越低，miR-499表达越低（P＜0.05）。SCLC组分期越晚，miR-486表达越低；而miR-499在不同临床特征患者间表达差异均无统计学意义。miR-486诊断肺癌的AUC为0.83（95%CI为0.73-0.93），敏感度和特异度分别为90.0%和68.6%，最佳诊断界值为1.02；miR-499诊断肺癌的AUC为0.75（95%CI为0.62-0.88），敏感度和特异度分别为60.0%和94.3%，对肺癌的最佳诊断界值为0.32。结论血浆miR-486、miR-499在肺癌患者中表达下调，可能预示预后不良，有望作为肺癌潜在筛查及预后的指标。Objective To explore the expression levels of mi R- 486 and mi R- 499 in the plasma of lung cancerpatients, and analyze their expression differences in non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC).Methods Blood samples were collected in 35 patients with lung cancer(21 NSCLC and 14 SCLC) and 30 healthy persons(control group). The real-time quantitative PCR was used to detect the expression levels of plasma mi R-486 and mi R-499 in two groups. The plasma levels of mi RNA- 486 and mi RNA-499 and their correlation with various clinical features inNSCLC and SCLC patients were analyzed. The receiver operating characteristic curves(ROC)of mi RNA expressions wereanalyzed. The area under a curve(AUC), threshold and the sensitivity and specificity were calculated. Results Theexpression levels of mi R-486 and mi R-499 were significantly lower in NSCLC and SCLC groups than those of the controlgroup(P<0.05). There were no significant differences in the expression of mi R- 486 between different clinical features inNSCLC group. For the late cancer TNM staging, the tumor differentiation was lower, and the mi R-499 expression level waslower(P<0.05). In SCLC group, for the late cancer staging, there was a lower expression level of mi R-486. There were nosignificant differences in the expressions of mi R- 499 between different clinical features. The mi RNA- 486 AUC in thediagnosis of lung cancer was 0.83(95% CI: 0.73- 0.93), the sensitivity and specialty rates were 90.0% and 68.6%respectively, and the best diagnostic value was 1.02. The mi RNA-499 AUC in the diagnosis of lung cancer was 0.75(95%CI: 0.62-0.88), the sensitivity and specialty rates were 60.0% and 94.3% respectively, and the best diagnostic boundaryvalue was 0.18 for lung cancer. Conclusion The plasma expression levels of mi R-499 and mi R-486 are down-regulatedin lung cancer patients, which suggest a poor prognosis and can be used as potential screening and prognostic indicators forlung cancer.

关 键 词：癌 非小细胞肺 血浆 敏感性与特异性 诊断 鉴别 miR-486 miR-499 

分 类 号：R734.2[医药卫生—肿瘤]